Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Current Liabilities (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Total Current Liabilities data on record, last reported at $87.9 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 47.58% year-over-year to $87.9 million; the TTM value through Sep 2025 reached $87.9 million, up 47.58%, while the annual FY2024 figure was $68.3 million, 51.04% up from the prior year.
  • Total Current Liabilities reached $87.9 million in Q3 2025 per NWBO's latest filing, up from $83.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $363.4 million in Q1 2021 and bottomed at $4.9 million in Q3 2023.
  • Average Total Current Liabilities over 5 years is $119.8 million, with a median of $83.9 million recorded in 2025.
  • Peak YoY movement for Total Current Liabilities: crashed 95.74% in 2023, then soared 1105.26% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $133.8 million in 2021, then decreased by 5.8% to $126.0 million in 2022, then crashed by 64.13% to $45.2 million in 2023, then skyrocketed by 51.04% to $68.3 million in 2024, then grew by 28.75% to $87.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $87.9 million in Q3 2025, $83.9 million in Q2 2025, and $83.1 million in Q1 2025.